Recent Updates
Recently added Catalysts

Concurrent Atezolizumab

Phase 1FDA approved 2016

Head and Neck Neoplasm | Biologics | Oncology |Roche Holding AG|Trials Updated: Sep 21, 2026

Concurrent Atezolizumab development status

FDA approval May 18, 2016 as Tecentriq
Approval holderGenentech Inc
ApplicationBLA761034
Highest phase Phase 1
Registered trials 1 across 1 sponsor since Jul 2020

Label indication TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-authorized test. FDA label

Concurrent Atezolizumab target and mechanism

ModalityBiologics

Also known as Tecentriq

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment18

FDA Designations

No designations recorded

Concurrent Atezolizumab clinical trials

Concurrent Atezolizumab · 1 trial · 1 indication

Phase 1 1
NCT04477759Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck CancerHead and Neck Neoplasm
COMPLETED18 Analytics
PHASE1COMPLETED
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Head and Neck NeoplasmUnlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of Dose-Limiting Toxicities at 50 Gy With Concurrent Atezolizumab
12 months

This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.

Incidence of Dose-Limiting Toxicities at 50 Gy
12 months

This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.

Incidence of Dose-Limiting Toxicities at 55 Gy
12 months

This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.

Incidence of Dose-Limiting Toxicities at 60 Gy
12 months

This measure is the number of subjects experiencing a dose-limiting toxicity. A dose-limiting toxicity is defined as an inability to complete radiation treatment within 30 days of the start of radiotherapy that is not deemed to be related to disease progression; OR an unacceptable toxicity within one year of treatment (Grade 4+ toxicity) that is probably or definitely related to radiation treatment as determined by the treating physician or a death within one year of treatment that is probably or definitely related to treatment.

Maximum Tolerated Radiation Dose
12 months

This measure is the highest radiation dose at which there is a 30% or more rate of dose-limiting toxicity up to 12 months after completion of radiation treatment using the TITE-CRM design.

Secondary Endpoints

Overall Survival
1 year
Locoregional Progression
1 year
Percent Change in Gross Tumor Volume From Baseline at Radiation Fraction 6
6th Radiation Fraction (approximately 1 week)
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
50 Gray (Gy) Radiation Therapy with Concurrent AtezolizumabEXPERIMENTAL50 Gy of ionizing radiation therapy will be administered in 15 fractions.
50 Gray (Gy) Radiation TherapyEXPERIMENTAL50 Gy of ionizing radiation therapy will be administered in 15 fractions.
55 Gray (Gy) Radiation TherapyEXPERIMENTAL55 Gy of ionizing radiation therapy will be administered in 15 fractions.
60 Gray (Gy) Radiation TherapyEXPERIMENTAL60 Gy of ionizing radiation therapy will be administered in 15 fractions.

Interventions

NameTypeDescription
50 Gy Radiation TherapyRADIATIONIonizing radiation
55 Gy Radiation TherapyRADIATIONIonizing radiation
60 Gy Radiation TherapyRADIATIONIonizing radiation
Concurrent AtezolizumabDRUGAtezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.
Adjuvant AtezolizumabDRUGAtezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 28 days following the initiation of radiation treatment up to 1 year.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Age ≥18 years * Diagnosis of T3-T4 N0-N3 M0 or T0-T4 N1-N3 M0 squamous cell carcinoma of the head and neck squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or carcinoma of unknown head/neck primary) based on American Joint Committee on Cancer guidel...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMOct 22, 2026NCT04477759TRIAL_REMOVED: changed
MEDIUMOct 22, 2026NCT04477759TRIAL_REMOVED: changed
MEDIUMOct 22, 2026NCT04477759TRIAL_REMOVED: changed

Frequently asked questions about Concurrent Atezolizumab

What is Concurrent Atezolizumab?

Concurrent Atezolizumab is an investigational monoclonal antibody being studied in oncology. It is being developed by Roche Holding AG under the ticker RHHBY. It has been evaluated in a Phase 1 clinical trial in patients with head and neck neoplasm, where it was given alongside dose-escalated hypofractionated adaptive radiotherapy.

What is Concurrent Atezolizumab used for in head and neck neoplasm?

Concurrent Atezolizumab has been studied in head and neck neoplasm as part of a treatment regimen combined with dose-escalated hypofractionated adaptive radiotherapy. The Phase 1 trial enrolled 18 adult participants of any sex in the United States. It is an investigational agent and is not established as an approved therapy for this condition.

Who makes Concurrent Atezolizumab?

Concurrent Atezolizumab is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor associated with the clinical development of this monoclonal antibody in oncology, including the Phase 1 study conducted in patients with head and neck neoplasm.

What phase is Concurrent Atezolizumab in?

Concurrent Atezolizumab is in Phase 1 development. The single registered trial, NCT04477759, is a completed Phase 1 study with 18 enrolled participants. The program is investigational and remains in clinical development, with no active trials currently listed for this asset.

What clinical trials is Concurrent Atezolizumab in?

Concurrent Atezolizumab has been evaluated in one clinical trial, NCT04477759, titled Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer. This completed Phase 1 study enrolled 18 adults in the United States and used a controlled design without randomization or double blinding.